首页 › 基金 › Lion Point Capital, LP › DYN
Lion Point Capital, LP 对 DYN 的持仓历史
DYNE THERAPEUTICS INC · 医疗保健
Lion Point Capital, LP 在 Q2 2026 的 13F 申报中披露持有 DYN(DYNE THERAPEUTICS INC)18,000 股,市值约 US$400K,约占其申报组合的 1.91%,在其申报持仓中市值排名第 20 位。 Lion Point Capital, LP 最近 3 个申报季度中有 3 个季度披露了 DYN 持仓,最早可追溯至 Q4 2025。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
Lion Point Capital, LP 对 DYN 的持仓演变
Lion Point Capital, LP 于 Q4 2025 首次披露 DYN 持仓:18,000 股(约 US$352K)。 该持仓在 Q2 2026 达到峰值 18,000 股,市值约 US$400K。 在 3 次申报中,Lion Point Capital, LP 的持股数量始终未变。 最近一期申报(Q2 2026)显示持股 18,000 股、市值约 US$400K。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2025 | 18.00K | $352.08K | 新进 |
| Q1 2026 | 18.00K | $326.34K | 持有 |
| Q2 2026 | 18.00K | $399.78K | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 DYN 与 13F 数据
DYN(DYNE THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 42 只申报持有 DYN,申报仓位最大的包括:Atlas Venture Life Science Advisors, LLC (US$151.0M), TCG Crossover Management, LLC (US$102.5M), FCPM III SERVICES B.V. (US$85.5M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 DYN 的基金
- Atlas Venture Life Science Advisors, LLC 6.80M 股 · $151.03M · Q2 2026
- TCG Crossover Management, LLC 4.62M 股 · $102.50M · Q2 2026
- FCPM III SERVICES B.V. 3.85M 股 · $85.47M · Q2 2026
- Vestal Point Capital, LP 3.38M 股 · $74.96M · Q2 2026
- ORBIMED ADVISORS LLC 3.24M 股 · $71.86M · Q2 2026
- Frazier Life Sciences Management, L.P. 3.15M 股 · $70.03M · Q2 2026
- ARMISTICE CAPITAL, LLC 3.09M 股 · $68.57M · Q2 2026
- PERCEPTIVE ADVISORS LLC 2.69M 股 · $59.73M · Q2 2026
- Logos Global Management LP 2.55M 股 · $56.64M · Q2 2026
- Venrock Adviser, LLC 2.17M 股 · $48.28M · Q2 2026
- Siren, L.L.C. 2.13M 股 · $47.29M · Q2 2026
- MPM BioImpact LLC 1.92M 股 · $42.69M · Q2 2026
更多关于 Lion Point Capital, LP
常见问题
How long has Lion Point Capital, LP held DYN?
Lion Point Capital, LP has disclosed DYN holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Lion Point Capital, LP's current position in DYN?
As of Q2 2026, Lion Point Capital, LP holds 18.00K shares of DYN (DYNE THERAPEUTICS INC), valued at $399.78K, representing 1.91% of its reported portfolio and ranking #20.
Has Lion Point Capital, LP been buying or selling DYN?
In the latest 13F filing (Q2 2026), Lion Point Capital, LP held unchanged its position in DYN. The position peaked in Q2 2026 at 18.00K shares.
Which other funds hold DYN?
Other major institutional holders of DYN include Atlas Venture Life Science Advisors, LLC, TCG Crossover Management, LLC, FCPM III SERVICES B.V., among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.